Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

Clicks: 193
ID: 273589
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent is associated with lower risk for Alzheimer’s disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases which are mediated in part by TNF and for which a TNF blocker is an approved treatment. The analysis compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. Adjusted odds ratios (AORs) were estimated using the Cochran-Mantel-Haenszel (CMH) method and presented with 95% confidence intervals (CIs) and p-values. RA was associated with a higher risk for AD (Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02–2.10), P-value
Reference Key
zhou2020plostumor Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mengshi Zhou;Rong Xu;David C. Kaelber;Mark E. Gurney;
Journal PloS one
Year 2020
DOI 10.1371/journal.pone.0229819
URL
http://dx.plos.org/10.1371/journal.pone.0229819
Keywords
dementia Rheumatoid Arthritis alzheimer's disease psoriasis methotrexate inflammatory diseases medical risk factors alzheimer's disease diagnosis and management

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.